Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBITDA (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBITDA for 4 consecutive years, with -$66.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 39.52% to -$66.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$199.0 million through Dec 2025, up 14.59% year-over-year, with the annual reading at -$199.0 million for FY2025, 14.59% up from the prior year.
  • EBITDA for Q4 2025 was -$66.0 million at Centessa Pharmaceuticals, down from -$53.9 million in the prior quarter.
  • The five-year high for EBITDA was -$23.3 million in Q2 2023, with the low at -$109.2 million in Q4 2024.
  • Average EBITDA over 4 years is -$49.9 million, with a median of -$46.8 million recorded in 2023.
  • The sharpest move saw EBITDA skyrocketed 64.52% in 2023, then tumbled 202.33% in 2024.
  • Over 4 years, EBITDA stood at -$43.0 million in 2022, then increased by 15.94% to -$36.1 million in 2023, then crashed by 202.33% to -$109.2 million in 2024, then surged by 39.52% to -$66.0 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$66.0 million, -$53.9 million, and -$50.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.